Supplemental Table 4. Change From Baseline to Week 26 in Scores for Other Efficacy Endpoints (observed cases)

Endpoint (Full Scale)	n	Placebo LS Mean (95% CI)	n	Lutikizumab LS Mean (95% CI)	LS Mean Difference (95% CI) Lutikizumab vs Placebo*	P Value Lutikizumab vs Placebo*
AUSCAN stiffness NRS-11, 0–10)	60	−1.9 (−3.0, −0.8)	50	−2.7 (−3.7, −1.6)	−0.8 (−1.6, 0.1)	0.07
Subject assessment of pain intensity, index hand (NRS-11, 0–10)	60	−2.0 (−3.1, −0.9)	50	−2.5 (−3.6, −1.4)	−0.5 (−1.4, 0.4)	0.27
PGA (NRS-11, 0–10)	60	−2.0 (−3.1, −0.9)	50	−2.4 (−3.5, −1.2)	−0.4 (−1.3, 0.6)	0.45
Grip strength, index hand, kg	61	2.1 (−1.6, 5.9)	52	3.0 (−0.9, 6.9)	0.9 (−2.6, 4.4)	0.63
SF-36 (0–100)	60		51			
Physical Component Summary		1.85 (−1.10, 4.79)		3.49 (0.65, 6.33)	1.7 (−0.7, 4.0)	0.17
Mental Component Summary		−0.17 (−3.55, 3.20)		0.40 (−2.97, 3.77)	0.6 (−2.1, 3.2)	0.67
PROMIS SF20a (0–100)	60	1.6 (−0.7, 3.9)	50	2.6 (0.3, 4.8)	1.0 (−0.8, 2.9)	0.28
MHQ, index hand total score (0–100)	60	14.4 (7.2, 21.5)	51	16.0 (8.9, 23.0)	1.6 (−4.1, 7.3)	0.58
Hand function		14.6 (6.7, 22.4)		14.3 (6.6, 22.0)	−0.3 (−6.5, 6.0)	0.93
Activities of daily living		13.7 (5.0, 22.4)		13.8 (5.4, 22.2)	0.1 (−6.8, 7.0)	0.97
Pain		−18.9 (−28.1,		−23.6 (−32.6, −	−4.7 (−12.0, 2.6)	0.20

						*P value
		−9.6)		14.5)		
Work performance		10.5 (0.2, 20.9)		15.9 (5.7, 26.0)	5.3 (−3.0, 13.6)	0.21
Aesthetics		10.8 (2.2, 19.4)		6.2 (–2.3, 14.6)	−4.7 (−11.5, 2.2)	0.18
Satisfaction with hand function		17.1 (6.8, 27.3)		22.2 (12.2, 32.2)	5.1 (−3.0, 13.2)	0.21
FIHOA	60	0.3 (−1.7, 2.3)	51	−0.8 (−2.8, 1.2)	−1.1 (−2.7, 0.6)	0.20

ANCOVA=analysis of covariance; AUSCAN=Australian/Canadian Osteoarthritis Hand Index; FIHOA, Functional Index for Hand Osteoarthritis; LS=least squares; MHQ=Michigan Hand Outcomes Questionnaire; NRS=numeric rating scale; PGA=patient global assessment of hand osteoarthritis status; PROMIS SF20a=Patient Reported Outcomes Measurement Information System Physical Function Questionnaire; SF-36=36-item short-form health survey.

*P values are from an ANCOVA model adjusted for treatment groups and country as factors, and including baseline value as a covariate.